Stock events for 4D Molecular Therapeutics, Inc. (FDMT)
Over the past six months, FDMT's stock has experienced several notable events. The company completed enrollment for the 4FRONT-1 Phase 3 trial, granted RSUs to new non-executive employees, and saw Barclays initiate coverage with an "Overweight" rating. Positive interim clinical data was announced from the 4D-710 AEROW Phase 1 trial, and the company announced protocol amendments to the 4D-1 and 4FRONT-2 Phase 3 clinical trials. RBC Capital raised its price target on FDMT, and a minor risk of shareholder dilution was noted. NovaBridge's Visara Division appointed a new Chief Medical Officer and Chair of Scientific Advisory Board. As of March 6, 2026, the stock price was down 1.85% from its previous closing price, down 12.22% in March 2026, and down 27.15% over the past six months.
Demand Seasonality affecting 4D Molecular Therapeutics, Inc.’s stock price
There is no information available to suggest demand seasonality for 4D Molecular Therapeutics, Inc.'s products and services. Demand for its product candidates would likely be driven by medical need rather than seasonal fluctuations.
Overview of 4D Molecular Therapeutics, Inc.’s business
4D Molecular Therapeutics, Inc. (FDMT) is a clinical-stage gene therapy company focused on developing genetic medicines using its proprietary Therapeutic Vector Evolution platform, operating within the Healthcare sector and the Biotechnology industry. The company aims to create customized adeno-associated virus (AAV) vectors to treat severe diseases across ophthalmology, pulmonology, and cardiology. Its major product candidates include 4D-150 for retinal vascular diseases, 4D-710 for cystic fibrosis lung disease, 4D-310 for Fabry disease, 4D-125 and 4D-110 for ophthalmology, 4D-175 for geographic atrophy and 4D-725 for alpha-1 anti-trypsin deficiency lung disease.
FDMT’s Geographic footprint
4D Molecular Therapeutics, Inc. operates in the United States, with its headquarters in Emeryville, California, and also has operations in the Netherlands.
FDMT Corporate Image Assessment
In the past year, 4D Molecular Therapeutics' brand reputation appears to be positively influenced by its clinical progress and analyst coverage. The announcement of positive interim clinical data for 4D-710 and the completion of enrollment for the 4FRONT-1 Phase 3 trial for 4D-150 are significant milestones. Analyst firms like Barclays initiating coverage with an "Overweight" rating and RBC Capital raising its price target suggest a favorable view from the financial community.
Ownership
4D Molecular Therapeutics is owned by a mix of institutional shareholders (39.80%), company insiders (22.28%), and retail investors (37.92%). Major institutional and individual owners include RA Capital Management LP, Goldman Sachs Group Inc, Viking Global Investors LP, Blackrock Inc, Vanguard Group Inc, State Street Corp, BVF Partners L.P., David Kirn, and Peter Kolchinsky.
